AIDS TREATMENT NEWS Issue #213, December 23, 1994
John S. James
The new program will allow Serono Laboratories, Inc., the company testing the drug for AIDS-related wasting, to charge to recover their cost for providing this expensive drug -- which can cost $150 per day for the initial treatment, though it may later be possible to reduce the dose. Serono has hired a reimbursement agency to help patients get paid by their insurance companies and other third-party payers, and will provide some drug without charge to those unable to pay.
The rules require that this program is available only to patients "who have tried a course of approved therapy with Megace and Marinol where the response has been determined to be poor and that continued treatment with those agents has been judged by the attending physicians to be of doubtful promise." There may be efforts to get this restriction removed. Megace and Marinol are both approved treatments for significant unexplained weight loss, but are widely regarded as unsatisfactory.
To use Serono's human growth hormone (brand name Serostim (TM)), a physician must first qualify as a site with Serono. Later, less paperwork is required to add each individual patient. Physicians should begin the process by calling the Serostim Information Line, 800/714-AIDS (800/714-2437). Patients also can call this number for information.
Note:
Human growth hormone has been an approved prescription drug for years in the U.S. for treatment of growth-hormone deficiency in children. But it is tightly restricted to prevent abuse by athletes, and very few people with AIDS have been able to obtain it from either of the companies which have long marketed it in this country. Serono's version of the drug has been approved in 50 countries, but not in the U.S. It appears to have been easier to obtain the Serono drug through the treatment IND route, than to modify the restrictions on the drug already here.
AIDS treatment activists have made major contributions to the development and access to growth hormone; without their work, the drug would not have been available to patients for a long time. ACT UP/Golden Gate and Project Inform, and the San Francisco AIDS Foundation have taken the lead, and Mother's Voices, ACT UP/New York, Treatment Action Group (TAG), and AIDS Project Los Angeles have provided critical assistance.
ACT UP/Golden Gate has produced a flyer describing the treatment IND program; it will be updated as required. To obtain a free copy, call 415/252-9200, and leave your name and address, slowly, on the voicemail.
[Physicians and patients should know that another alternative for treating wasting syndrome, thalidomide, is currently in clinical trials. The ACT UP flyer on human growth hormone also includes information on thalidomide.]
941223
ATN21303
Copyright © 1994 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .